• 1
    Fraser IS. Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems. Contraception. 2012 Oct 4. pii: S0010-7824(12)00805-0. doi: 10.1016/j.contraception.2012.08.039. [Epub ahead of print]
  • 2
    Hee L, Kettner LO, Vejtorp M. Continuous use of oral contraceptives: an overview of effects and side-effects. Acta Obstet Gynecol Scand. 2012 Oct 20. doi: 10.1111/aogs.12036. [Epub ahead of print]
  • 3
    Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand. 2012 Jan;91:39.
  • 4
    Vercellini P, Crosignani P, Somigliana E, Viganò P, Frattaruolo MP, Fedele L. ‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum Reprod. 2011 Jan;26:313.
  • 5
    Becker JH, Kuipers LJ, Schuit E, Visser GH, Van Den Akker ES, Van Beek E,et al. Predictive value of the baseline T-QRS ratio of the fetal electrocardiogram in intrapartum fetal monitoring: a prospective cohort study. Acta Obstet Gynecol Scand. 2012 Feb;91:18997.
  • 6
    Amer-Wåhlin I, Kjellmer I, Maršál K, Olofsson P, Rosén KG. Swedish randomized controlled trial of cardiotocography only versus cardiotocography plus ST analysis of fetal electrocardiogram revisited: analysis of data according to standard versus modified intention-to-treat principle. Acta Obstet Gynecol Scand. 2011 Sep;90:9906.
  • 7
    Yli BM, Kessler J, Eikeland T, Hustad BL, Dragnes W, Henriksen T. What is the gold standard for intrapartum fetal monitoring? Acta Obstet Gynecol Scand. 2012 Sep;91:10114.
  • 8
    WHO, UNICEF, UNFPA, the World Bank. Trends in maternal mortality: 1990 to 2010. Geneva: WHO, UNICEF, UNFPA and The World Bank estimatesWorld Health Organization, 2012.